SPL7013 COVID-19 nasal spray virucidal against SARS-CoV-2
Filed with ASX · · 3 pages · English
New data generated at Scripps Research Institute in the US shows that Starpharma’s antiviral nasal spray active (SPL7013) is virucidal, inactivating more than 99.9% of SARS-CoV-2, the virus that causes COVID-19 Potent antiviral activity of SPL7013 against SARS-CoV-2 was evident when used either before or after exposure of cells to the virus meaning that the nasal spray could be used before or
Starpharma Holdings Limited on 6ix
Earlier from Starpharma
- Starpharma awarded $1M MRFF funding for COVID-19 spray
- SPL creates slow release soluble DEP remdesivir nanoparticle
- SPL7013 nasal spray for COVID19 development update
- Starpharma signs new DEP partnership with Chase Sun
- DEP irinotecan boosts immuno-oncology in colon cancer models
Later from Starpharma
- Starpharma completes oversubscribed A$45M placement
- Share Purchase Plan offer document
- Starpharma receives $5.7M R&D tax incentive refund
- Completion of Placement and SPP raises $48.9M in total
- SPL7013 shows potent antiviral activity in RSV
Follow Starpharma into a list and get an email when it puts out news.
Follow Starpharma